A U.S. Spine slump pressured results as management pushes a recovery plan.
OFIX Orthofix Medical Inc. Common Stock (DE)
XNAS
7.50
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
OFIX
$7.50
—
What changed
Recent filings, trades and movesKey stats
$7.50
- 52-Week Range
- $6.52 – $16.42
- YTD
- -49.46%
- IV Rank (30D)
- 51.71
- Straddle Price
- $2.65
- P/C Vol Ratio
- 0.26
- Market Cap
- $0.3B
- Open
- $7.01
- Day Range
- $6.52 – $7.59
- Volume
- 1,445,379
- Prev Close
- $7.87
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.08 |
| Cost of Equity (CAPM) | 10.84% (VRP-adj) |
| WACC | 8.60% |
| Volatility Risk Premium | +58.1pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +2.6% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -14.4% |
| Book / Price | 133.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 71.3% |
| FCF Margin (TTM) | -3.3% |
| Debt / Equity | 0.55 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $9.29 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $9.43 |
| Bollinger Width / SMA20 | 23.1% (drives anchor stability) |
| Net Debt | $0.1B |
| Market Cap | $0B |
Peers used for multiples: ABT, BDX, GEHC, MDT
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$26.28
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 33.7× · 4 peers |
| Peer EV/EBITDA | $7.02 | 17% | median 14.7× · 4 peers |
| Peer P/B | $31.11 | 22% | median 3.0× · 4 peers |
| Peer P/S | $66.44 | 22% | median 3.2× · 4 peers |
| Market Anchor (SMA50) | $9.29 | 39% | stability 35% (BB-width) |
| Options Expected (B-L 30d) | $9.36 | 0% | 5 strikes · skew -0.29 |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.3B
- Employees
- 1,605
- List Date
- 1992-04-24
- CIK
- 0000884624
- Next Earnings
- 2026-11-09 (Pre-Market)
- EPS Forecast
- ($0.27)
- Headquarters
- Lewisville, TX
- Homepage
- https://www.orthofix.com
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -6.15% | -6.09% | 1.31% | 5.79% | 6.20% | -10.85% | -1.63% |
| Feb | 14.30% | 11.41% | -4.36% | -8.48% | -4.51% | 0.59% | 1.49% |
| Mar | -7.11% | -1.77% | -17.00% | 11.69% | -3.95% | -14.21% | -5.39% |
| Apr | 3.31% | -6.17% | 13.57% | -7.54% | -13.12% | 1.29% | -1.44% |
| May | -9.15% | -11.47% | -2.15% | 5.41% | -16.97% | -22.17% | -9.42% |
| Jun | -3.97% | -13.55% | -3.83% | -3.77% | 2.86% | -1.40% | -3.94% |
| Jul | -3.40% | 5.60% | 8.97% | 24.84% | -1.25% | 23.30% | 9.68% |
| Aug | 6.96% | -23.17% | 6.76% | 10.59% | 39.09% | -23.41% | 2.80% |
| Sep | -10.89% | -3.29% | -39.57% | -6.63% | -1.68% | -0.21% | -10.38% |
| Oct | -8.47% | -15.83% | -13.21% | 5.89% | 7.67% | -1.52% | -4.25% |
| Nov | -16.98% | 10.98% | 0.18% | 15.15% | 0.19% | -13.43%* | -0.65% |
| Dec | 1.14% | 3.32% | 21.22% | -9.58% | -4.41% | -- | 2.34% |
| Total | -36.45% | -44.11% | -36.32% | 44.14% | 0.64% | -51.96% | -20.67% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $9.35
SMA 50: $9.25
SMA 200: $10.94
Current: $7.59
EMA 12: $8.91
EMA 26: $9.19
MACD: -0.2860 | Signal: -0.2125
BEARISH
ADX (14): 19.25
RANGE
+DI: 19.30
−DI: 41.83
Momentum Oscillators
RSI (14): 33.32
NEUTRAL
Stoch %K: 15.68
Stoch %D: 23.56
Williams %R: -73.46
Volume & Volatility
BB Upper: $10.70
BB Lower: $8.00
OVERSOLD
OBV: -6,797,832
Vol SMA 20: 540,034
Vol ROC: 616.68%
ATR: $0.65
True Range: $1.35
HV 20: 85.3%
HV 30: 72.3%
HV 60: 56.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before OFIX’s Nov 9 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report - Orthofix Inc. (OFIX)
Executive Summary
Overall Assessment: NEUTRAL with a confidence level of 6/10
Key Drivers and Primary Risks:
- Strong sector performance in the medical device industry
- Positive news sentiment driven by advancements in regenerative therapies and rising osteoarthritis cases
- Technical indicators suggesting a range-bound market with no clear trend direction
Recent News Sentiment Impact: The recent news headlines are predominantly positive, driving bullish momentum. However, the negative headlines related to investor lawsuits and regulatory issues may lead to some caution.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Range-bound market with no clear trend direction
- Medium-term (1-3 months): Consolidation phase after a previous decline
- Long-term (3-12 months): Uptrend intact, but consolidation is ongoing
Support/Resistance Levels:
- Key price levels:
- Lower support: $9.51 (Bollinger Band lower)
- Middle support: $10.59 (SMA 50)
- Upper resistance: $12.70 (Bollinger Band upper)
Momentum Signals:
- RSI interpretation: Neutral, suggesting no clear trend direction
- MACD signal: Bearish, but the histogram is declining, indicating a potential buy signal
- Bollinger Bands position: Squeeze, suggesting volatility may increase
Volume Analysis:
- Volume trends:
- Short-term (1-4 weeks): Low volume, indicating market indecision
- Medium-term (1-3 months): Higher volume on recent price movements
- Institutional interest signals: No clear signs of institutional buying or selling pressure
News & Sentiment Analysis
Recent Headlines Summary: The news headlines are primarily positive, driven by advancements in regenerative therapies and rising osteoarthritis cases.
Sentiment Assessment: Positive, with a sentiment score of 80% (4 out of 5 articles having a positive tone).
Catalyst Identification: Upcoming regulatory developments and product launches may drive market momentum.
Market Narrative: The news aligns with the technical signals, suggesting a range-bound market with no clear trend direction.
Risk & Volatility Assessment
Beta Interpretation: Low-risk stock with a beta of 0.69 (less volatile than the market).
Volatility Regime: Low volatility, indicating stable price movements.
Options Market Signals:
- IV rank: 60.7% (Medium), suggesting historically high volatility
- Current IV: 135.8%, indicating high implied volatility
- Expected Move: $1.75 (32 DTE), 7-DTE: $0.95, suggesting a moderate move
Downside Protection: Support levels are in place, and the stock is trading within a relatively tight range.
Market Context & Positioning
Sector Performance: The medical device industry is performing well, driving bullish sentiment.
Institutional Activity: No clear signs of institutional buying or selling pressure.
Correlation Analysis: Correlation with the market is low (0.19), indicating limited sensitivity to broader market movements.
Relative Valuation: The stock is trading within a relatively tight range, suggesting fair valuation.
Key Levels & Action Items
Critical Price Levels:
- Lower support: $9.51
- Middle support: $10.59
- Upper resistance: $12.70
Breakout/Breakdown Levels: No clear breakout or breakdown levels are present.
Time-Sensitive Catalysts: Regulatory developments and product launches may drive market momentum in the near term.
Risk Management: Stop-loss levels should be set around $9.51, considering the potential for a bounce back up to $10.59. Position sizing considerations include limiting exposure to 2-3% of overall portfolio.
Generated
News
All OFIX news →
Earnings History
17 of 18 under expected move
Avg Expected Move
14.96%
Avg Actual Move
5.44%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-08-06 | Pre-Market | 13.82% | 6.85% | 0.50x | Within |
| 2021-11-05 | Pre-Market | 5.54% | 2.93% | 0.53x | Within |
| 2022-02-25 | Pre-Market | 16.19% | 1.32% | 0.08x | Within |
| 2023-05-09 | Pre-Market | 9.83% | 0.81% | 0.08x | Within |
| 2023-08-08 | Pre-Market | 13.39% | 3.02% | 0.23x | Within |
| 2023-11-08 | Pre-Market | 12.43% | 2.39% | 0.19x | Within |
| 2024-01-09 | Pre-Market | 9.78% | 9.78% | 1.00x | Within |
| 2024-03-05 | Pre-Market | 8.42% | 0.54% | 0.06x | Within |
| 2024-05-07 | Pre-Market | 15.60% | 3.19% | 0.20x | Within |
| 2024-08-06 | Pre-Market | 16.45% | 19.53% | 1.19x | Exceeded |
| 2024-11-07 | Pre-Market | 14.13% | 0.98% | 0.07x | Within |
| 2025-02-25 | Pre-Market | 15.29% | 3.53% | 0.23x | Within |
| 2025-05-06 | Pre-Market | 14.03% | 10.93% | 0.78x | Within |
| 2025-08-05 | After-Close | 20.11% | 1.87% | 0.09x | Within |
| 2025-11-04 | Pre-Market | 19.93% | 7.41% | 0.37x | Within |
| 2026-02-24 | Pre-Market | 21.89% | 6.18% | 0.28x | Within |
| 2026-05-05 | After-Close | 20.10% | 2.01% | 0.10x | Within |
| 2026-08-05 | Pre-Market | 22.34% | 14.59% | 0.65x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
OFIX Options Activity & IV Rank
OFIX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 107.3%
7-DTE IV: —
Expected Move: $2.65
7-DTE Move: $1.57
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 187
Put Volume: 48
P/C Volume: 0.257
BULLISH
Call OI: 158
Put OI: 241
P/C OI: 1.525
Total OI: 399
ATM Options Pricing
ATM Call: $1.25
ATM Put: $1.40
Call %: 16.7%
Put %: 18.7%
Chain Summary
Chain Volume: 235
Chain OI: 399
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 2nd percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
2%
vs own history
GEX tilt
-0.81
OI-weighted, today
Vanna tilt
+0.25
δ-sensitivity to IV
Charm tilt
-0.08
δ-decay vs time
? What is this?
· 4 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)51.7MediumNov 9
Straddle Price (30 DTE)$2.65Nov 9
Beta Analysis
Risk Metrics
Beta: 0.9201
Alpha: -66.72%
Correlation: 0.2488
R-Squared: 6.2%
Stock Volatility: 50.9%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own OFIX
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $7.9M | #1760 of 3716 | -19.2% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $885K | #2368 of 3138 | -5.1% | 13F | |
| Point72 Hedge fund Steve Cohen | $667K | #1580 of 1945 | -54.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $452K | #4579 of 6285 | -60.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
OFIX Institutional Ownership (13F)
Filings for 2026-06-30 · 44 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 40,181,086 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
OFIX Insider Trading (Form 4)
Latest: 2026-11-04Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-04 | Patrick Fisher | President, Global Limb Recon | Sell (S) | −150 | $9.07 | -$1.4K | EDGAR |
| 2026-10-05 | Patrick Fisher | President, Global Limb Recon | Sell (S) | −150 | $9.44 | -$1.4K | EDGAR |
| 2026-09-23 | Juniper Investment Company, LLC | 10%+ Owner | Buy (P) | +310,000 | $8.81 | $2.73M | EDGAR |
| 2026-09-22 | Alexis P Michas | 10%+ Owner | Sell (S) | +310,000 | $8.81 | $2.73M | EDGAR |
| 2026-09-03 | Patrick Fisher | President, Global Limb Recon | Sell (S) | −150 | $9.39 | -$1.4K | EDGAR |
| 2026-08-20 | Patrick Fisher | President, Global Limb Recon | Sell (S) | −1,295 | $10.09 | -$13.1K | EDGAR |
| 2026-08-18 | Alexis P Michas | 10%+ Owner | Sell (S) | +39,500 | $10.20 | $402.7K | EDGAR |
| 2026-06-22 | Aviva McPherron | Pres, Global Ops & Qual | Sell (S) | −3,670 | $9.38 | -$34.4K | EDGAR |
| 2026-06-12 | Michael E Paolucci | Director | Award (A) | +14,965 | — | EDGAR | |
| 2026-06-12 | Charles R. Kummeth | Director | Award (A) | +14,965 | — | EDGAR | |
| 2026-06-12 | John B Henneman III | Director | Award (A) | +14,965 | — | EDGAR | |
| 2026-06-12 | Michael Finegan | Director | Award (A) | +20,721 | — | EDGAR | |
| 2026-06-12 | Vickie L Capps | Director | Award (A) | +14,965 | — | EDGAR | |
| 2026-06-12 | Jason Hannon | Director | Award (A) | +14,965 | — | EDGAR | |
| 2026-06-12 | Shweta Maniar | Director | Award (A) | +14,965 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
OFIX Insider Holdings
25 insiders · @ $7.59
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | ENGINE CAPITAL, L.P. | 10%+ Owner | 3,783,131 | $28.73M | $2.23M | 1 | 2026-05-07 |
| 2 | Engine Investments II, LLC | 10%+ Owner | 3,673,092 | $27.90M | $1.73M | 1 | 2026-02-26 |
| 3 | Juniper Investment Company, LLC | 10%+ Owner | 3,581,216 | $27.20M | $2.73M | 1 | 2026-09-23 |
| 4 | Engine Capital Management, LP | 10%+ Owner | 362,212 | $2.75M | $1.23M | 1 | 2025-05-14 |
| 5 | Engine Jet Capital, L.P. | 10%+ Owner | 362,212 | $2.75M | $13.9K | 1 | 2025-07-07 |
| 6 | Arnaud Ajdler | 10%+ Owner | 344,652 | $2.62M | $1.23M | 1 | 2025-05-08 |
| 7 | Massimo Calafiore | President & CEO | 320,136 | $2.43M | -$485.8K | 8 | 2026-03-06 |
| 8 | Lucas Vitale | CP&BOO | 160,449 | $1.22M | -$151.5K | 5 | 2026-03-19 |
| 9 | John B Henneman III | Director | 105,774 | $803.4K | $61.3K | 6 | 2026-06-12 |
| 10 | Michael E Paolucci | Director | 102,727 | $780.2K | $62.3K | 14 | 2026-06-12 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
OFIX Board & Officers
As of SEC filings through Nov 4, 2026Directors 10
- Michael E Paolucci · since Mar 16, 2016
- Jason Hannon · since Jun 8, 2020
- Wayne Burris · since Sep 22, 2021
- John B Henneman III · since Jan 5, 2023
- Shweta Maniar · since Jan 5, 2023
- Alan Lee Bazaar · since Dec 12, 2023
- Charles R. Kummeth · since Dec 14, 2023
- Michael Finegan · listed since Dec 2023
- Massimo Calafiore · listed since Jan 2024
- Vickie L Capps · since Mar 11, 2025
Officers 6
- Massimo Calafiore · President & CEO · since Jan 8, 2024
- Patrick Fisher · President, Global Limb Recon · listed since Mar 2026
- Julie Andrews · CFO · since Jan 15, 2024
- Jorge Andres Cedron · CLO · since Apr 15, 2024
- Lucas Vitale · Cp&boo · listed since Mar 2025
- Aviva McPherron · Pres, Global Ops & Qual · since May 1, 2025
10% owners 11
- Alexis P Michas · since May 21, 2026
- Arnaud Ajdler · since May 6, 2025
- Engine Capital Management GP, LLC (entity) · since May 6, 2025
- Engine Capital Management, LP (entity) · since May 6, 2025
- Engine Capital, L.p. (entity) · since May 6, 2025
- Engine Investments II, LLC (entity) · since May 6, 2025
- Engine Investments, LLC (entity) · since May 6, 2025
- Engine Jet Capital, L.P. (entity) · since May 6, 2025
- Engine Lift Capital, LP (entity) · since May 6, 2025
- John A. Bartholdson · since May 21, 2026
- Juniper Investment Company, LLC (entity) · since May 21, 2026
Changes in the last 10 years (71)
| May 21, 2026 | Juniper Investment Company, LLC became a 10% owner |
| May 21, 2026 | John A. Bartholdson became a 10% owner |
| May 21, 2026 | Alexis P Michas became a 10% owner |
| Apr 9, 2026 | The company announced the departure of Max Reinhardt as President, Global Spine in an SEC filing |
| Mar 5, 2026 | Patrick Fisher listed as President, Global Limb Recon (previously President, Global Orthopedics) in SEC filings |
| May 6, 2025 | Engine Lift Capital, LP became a 10% owner |
| May 6, 2025 | Engine Jet Capital, L.P. became a 10% owner |
| May 6, 2025 | Engine Investments, LLC became a 10% owner |
| May 6, 2025 | Engine Investments II, LLC became a 10% owner |
| May 6, 2025 | Engine Capital, L.p. became a 10% owner |
| May 6, 2025 | Engine Capital Management, LP became a 10% owner |
| May 6, 2025 | Engine Capital Management GP, LLC became a 10% owner |
| May 6, 2025 | Arnaud Ajdler became a 10% owner |
| May 1, 2025 | Aviva McPherron became Pres, Global Ops & Qual |
| Mar 20, 2025 | Lucas Vitale listed as Cp&boo (previously Cp&bo) in SEC filings |
| Mar 11, 2025 | Vickie L Capps became a director |
| Aug 15, 2024 | Patrick Fisher became President, Global Orthopedics |
| Jun 20, 2024 | The company announced the departure of Kimberley A. Elting as President, Global Orthopedics in an SEC filing |
| Jun 18, 2024 | Lucas Vitale became Cp&bo |
| Jun 10, 2024 | Max Reinhardt became President, Global Spine |
| Apr 15, 2024 | Jorge Andres Cedron became CLO |
| Apr 11, 2024 | The company announced the departure of Stuart Essig from the board in an SEC filing |
| Apr 11, 2024 | The company announced the departure of James F. Hinrichs from the board in an SEC filing |
| Mar 19, 2024 | Geoffrey C Gillespie listed as CAO (previously VP, Controller, Interim CFO) in SEC filings |
| Jan 23, 2024 | Massimo Calafiore first listed as a director in an SEC filing |
| Jan 15, 2024 | Julie Andrews became CFO |
| Jan 9, 2024 | Kevin J. Kenny reported in an SEC filing no longer being President of Global Spine |
| Jan 8, 2024 | Massimo Calafiore became President & CEO |
| Dec 20, 2023 | Michael Finegan no longer listed as Chief Strategy Officer in SEC filings |
| Dec 20, 2023 | Michael Finegan first listed as a director in an SEC filing |
| Dec 14, 2023 | Charles R. Kummeth became a director |
| Dec 12, 2023 | Alan Lee Bazaar became a director |
| Nov 27, 2023 | The company announced the departure of Catherine M Burzik from the board in an SEC filing |
| Oct 17, 2023 | Catherine M Burzik first listed as Interim CEO in an SEC filing |
| Sep 12, 2023 | Puja Leekha became CECO & Interim CLO |
| Sep 12, 2023 | Geoffrey C Gillespie became VP, Controller, Interim CFO |
| Sep 11, 2023 | The company announced the departure of Keith Valentine from the board in an SEC filing |
| Jan 11, 2023 | Thomas A. West reported in an SEC filing no longer being a director |
| Jan 11, 2023 | Lilly Marks reported in an SEC filing no longer being a director |
| Jan 9, 2023 | Jon Carl Serbousek listed as Executive Chairman (previously CEO) in SEC filings |
| Jan 9, 2023 | John J. Bostjancic first on file as CFO |
| Jan 5, 2023 | Stuart Essig became a director |
| Jan 5, 2023 | Shweta Maniar became a director |
| Jan 5, 2023 | Keith Valentine became a director |
| Jan 5, 2023 | Keith Valentine became President & CEO |
| Jan 5, 2023 | John B Henneman III became a director |
| Jan 3, 2023 | The company announced the departure of John Sicard from the board in an SEC filing |
| Apr 13, 2022 | Kimberley A. Elting listed as President, Global Orthopedics (previously Chief Legal & Develop. Officer) in SEC filings |
| Apr 5, 2022 | The company announced the departure of Paul Gonsalves as President, Global Orthopedics in an SEC filing |
| Jan 5, 2022 | Patrick L Keran became Chief Legal Officer |
| Dec 13, 2021 | Thomas A. West became a director |
| Sep 22, 2021 | Wayne Burris became a director |
| Sep 13, 2021 | Paul Gonsalves listed as President, Global Orthopedics (previously President, Global Extremities) in SEC filings |
| Jun 21, 2021 | Catherine M Burzik became a director |
| Sep 15, 2020 | Kimberley A. Elting listed as Chief Legal & Develop. Officer (previously Chief Legal & Admin Officer) in SEC filings |
| Sep 11, 2020 | Paul Gonsalves became President, Global Extremities |
| Jun 8, 2020 | Jason Hannon became a director |
| Dec 4, 2019 | Kevin J. Kenny became President of Global Spine |
| Nov 5, 2019 | Jon Carl Serbousek listed as CEO (previously President of Global Spine) in SEC filings |
| Nov 5, 2019 | Jon Carl Serbousek first listed as a director in an SEC filing |
| Nov 4, 2019 | Brad Mason reported in an SEC filing no longer being a director |
| Nov 4, 2019 | Brad Mason reported in an SEC filing no longer being CEO |
| Aug 5, 2019 | Jon Carl Serbousek became President of Global Spine |
| Jul 15, 2019 | Bradley V. Niemann reported in an SEC filing no longer being President of Global Spine |
| Feb 20, 2019 | Davide Bianchi listed as President, Global Extremities (previously President Extremity Fixation) in SEC filings |
| Sep 10, 2018 | Kimberley A. Elting listed as Chief Legal & Admin Officer (previously Chief Legal Officer) in SEC filings |
| Jul 5, 2018 | Bradley V. Niemann listed as President of Global Spine (previously President Biostim) in SEC filings |
| Mar 12, 2018 | John Sicard became a director |
| Nov 30, 2017 | Brad Mason first listed as a director in an SEC filing |
| Jul 10, 2017 | Davide Bianchi listed as President Extremity Fixation (previously Pres, Extremity Fixation) in SEC filings |
| Dec 13, 2016 | Alexis V Lukianov became a director |
Not reported recently (15)
- Geoffrey C Gillespie · Last reported as CAO in an SEC filing dated Apr 4, 2025
- Catherine M Burzik · Last reported as Interim CEO in an SEC filing dated Oct 17, 2023
- Puja Leekha · Last reported as CECO & Interim CLO in an SEC filing dated Oct 17, 2023
- Jon Carl Serbousek · Last reported as a director in an SEC filing dated Apr 5, 2023
- Patrick L Keran · Last reported as Chief Legal Officer in an SEC filing dated Mar 2, 2023
- Keith Valentine · Last reported as President & CEO in an SEC filing dated Mar 2, 2023
- John J. Bostjancic · Last reported as CFO in an SEC filing dated Mar 2, 2023
- Rice Doug · Last reported as CFO in an SEC filing dated Apr 13, 2022
- Alexis V Lukianov · Last reported as a director in an SEC filing dated Jun 23, 2021
- Maria Sainz · Last reported as a director in an SEC filing dated Jun 10, 2020
- Ronald A Matricaria · Last reported as a director in an SEC filing dated Jun 10, 2020
- Davide Bianchi · Last reported as President, Global Extremities in an SEC filing dated Jul 10, 2019
- Luke T Faulstick · Last reported as a director in an SEC filing dated Nov 6, 2018
- Raymond Fujikawa · Last reported as President Spine Fixation in an SEC filing dated Jun 21, 2018
- Robert Allen Goodwin II · Last reported as President Biologics in an SEC filing dated Apr 3, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
OFIX Proposed Insider Sales (Form 144)
Latest: 2026-09-01
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $4K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
PATRICK FISHER (1, $4K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-01 | PATRICK FISHER | Officer | 450 | $4.2K | 2026-09-01 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2023-12-21 | Valentine Keith | Director | 66,665 | $926.0K | 2023-12-18 | Merrill Lynch | — | EDGAR |
| 2023-11-20 | Bostjancic John J. | Officer | 33,456 | $368.0K | 2023-11-20 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2023-11-09 | Bostjancic John J. | Officer | 9,084 | $98.1K | 2023-11-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2023-11-09 | Keran Patrick L | Officer | 28,985 | $318.8K | 2023-11-09 | MORGAN STANLEY SMITH BARNEY LLC,… | — | EDGAR |
| 2023-05-24 | Kenny Kevin J. | Officer | 10,119 | $192.3K | 2023-05-24 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-08-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-05 | 0001193125-26-333822 | EDGAR |
ETF Holders
46 ETFs hold OFIX
25 shown · $45.18M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $11.4M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $8.1M | $76.6B | 2026-11-06 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $4.2M | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.02% | $2.9M | $13.9B | 2026-11-06 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $2.2M | — | 2026-09-30 |
| 6 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $2.0M | — | 2026-11-05 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.8M | — | 2026-08-31 |
| 8 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 0.04% | $1.6M | $4.0B | 2026-11-06 |
| 9 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.02% | $1.5M | $6.6B | 2026-11-05 |
| 10 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.02% | $1.2M | — | 2026-11-05 |
| 11 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.08% | $962,123 | $1.2B | 2026-11-06 |
| 12 | VHT Vanguard Health Care ETF | Vanguard | 0.00% | $921,267 | — | 2026-09-30 |
| 13 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $894,944 | — | 2026-11-05 |
| 14 | XHE State Street® SPDR® S&P® Health Care Equipment ETF | SPDR (State Street) | 0.47% | $743,475 | $158.1M | 2026-11-05 |
| 15 | ISMD Inspire Small/Mid Cap ETF | Nport | 0.21% | $702,147 | — | 2026-08-31 |
| 16 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.02% | $633,338 | $3.2B | 2026-11-05 |
| 17 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.06% | $625,943 | $1.0B | 2026-11-05 |
| 18 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.02% | $465,899 | — | 2026-07-31 |
| 19 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.01% | $451,911 | $4.2B | 2026-11-06 |
| 20 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $423,508 | $93.2B | 2026-11-06 |
| 21 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.03% | $350,344 | — | 2026-09-30 |
| 22 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.00% | $321,486 | — | 2026-11-05 |
| 23 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.01% | $320,860 | — | 2026-06-30 |
| 24 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $234,168 | — | 2026-08-31 |
| 25 | VFVA Vanguard U.S. Value Factor ETF | Vanguard | 0.02% | $231,412 | — | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.53
TTM Revenue
$833.19M
TTM Net Income
$-61.72M
TTM Op. Cash Flow
$16.27M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $210.93M | $-15.80M | $-0.39 | $-6.22M |
| Q1 '26 | 2026-03-31 | $196.71M | $-20.91M | $-0.52 | $-17.61M |
| Q4 '25 | 2025-12-31 | $219.91M | $-2.22M | $-0.05 | $27.70M |
| Q3 '25 | 2025-09-30 | $205.63M | $-22.80M | $-0.57 | $12.40M |
| Q2 '25 | 2025-06-30 | $203.12M | $-14.08M | $-0.36 | $11.64M |
| Q1 '25 | 2025-03-31 | $193.65M | $-53.09M | $-1.35 | $-18.39M |
| Q4 '24 | 2024-12-31 | $215.66M | $-29.15M | $-0.75 | $23.73M |
| Q3 '24 | 2024-09-30 | $196.61M | $-27.39M | $-0.71 | $11.67M |
| Q2 '24 | 2024-06-30 | $198.62M | $-33.44M | $-0.88 | $8.98M |
| Q1 '24 | 2024-03-31 | $188.61M | $-36.02M | $-0.95 | $-18.59M |
| Q4 '23 | 2023-12-31 | $200.41M | $-22.17M | $-0.59 | $-8.79M |
| Q3 '23 | 2023-09-30 | $184.01M | $-28.86M | $-0.77 | $1.28M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.71
P/S
0.37
EV/EBITDA
15.71
EV/Sales
0.52
ROE
-14.4%
ROA
-7.1%
Div Yield
0.00%
FCF Yield
5.34%
Debt/Equity
0.55
Current Ratio
—
Market Cap
$304.37M
as of 2026-11-09
OFIX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ABT Abbott Laboratories | $190.4B | 40.9 | +10.0% | −11.1% | 20 |
| ISRG Intuitive Surgical Inc. | $160.0B | 55.8 | +20.5% | −17.9% | 18 |
| MDT Medtronic plc | $130.2B | 25.4 | +9.8% | +7.6% | 59 |
| SYK Stryker Corporation | $124.1B | 34.8 | +7.9% | −6.2% | 31 |
| EW Edwards Lifesciences Corp | $58.7B | 60.3 | +14.6% | +22.9% | 20 |
| BDX Becton, Dickinson and Co. | $57.7B | 54.7 | +6.4% | +10.9% | 30 |
| IDXX Idexx Laboratories Inc | $53.3B | 47.7 | +11.9% | +5.7% | 21 |
| GEHC GE HealthCare Technologies Inc. Common S | $37.2B | 17.8 | +6.9% | +2.0% | 30 |
| OFIX Orthofix Medical Inc. Common Stock (DE) | $321M | — | +3.0% | −48.8% | 52 |
| Peer median | $91.4B | 44.3 | +9.9% | +3.8% | 25 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.39M
SI % of Float
6.05%
Days to Cover
5.79
Short Vol Ratio
30.7%
Free Float
39.52M
Float %
97.0%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14